Gallium in cancer treatment
P Collery, B Keppler, C Madoulet, B Desoize - Critical reviews in oncology …, 2002 - Elsevier
Gallium (Ga) is the second metal ion, after platinum, to be used in cancer treatment. Its activities
are numerous and various. It modifies three-dimensional structure of DNA and inhibits its …
are numerous and various. It modifies three-dimensional structure of DNA and inhibits its …
Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy
F Kratz, U Beyer, T Roth, N Tarasova, P Collery… - Journal of …, 1998 - Elsevier
□ One strategy for improving the antitumor selectivity and toxicity profile of antitumor agents
is to design drug carrier systems employing suitable carrier proteins. Thus, thiolated human …
is to design drug carrier systems employing suitable carrier proteins. Thus, thiolated human …
Strategies for the development of selenium-based anticancer drugs
P Collery - Journal of Trace Elements in Medicine and Biology, 2018 - Elsevier
Many experimental models demonstrated that inorganic and organic selenium (Se) compounds
may have an anticancer activity. However, large clinical studies failed to demonstrate …
may have an anticancer activity. However, large clinical studies failed to demonstrate …
Design of rhenium compounds in targeted anticancer therapeutics
P Collery, D Desmaele… - Current Pharmaceutical …, 2019 - ingentaconnect.com
Background: Many rhenium (Re) complexes with potential anticancer properties have been
synthesized in the recent years with the aim to overcome the clinical limitations of platinum …
synthesized in the recent years with the aim to overcome the clinical limitations of platinum …
[HTML][HTML] Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
P Collery, A Mohsen, A Kermagoret, S Corre… - Investigational new …, 2015 - Springer
Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound,
combining one atom of rhenium and two atoms of selenium. This compound has been reported …
combining one atom of rhenium and two atoms of selenium. This compound has been reported …
Dichlorotetra-μ-isobutyratodirhenium (III): enhancement of cisplatin action and RBC-stabilizing properties
N Shtemenko, P Collery, A Shtemenko - Anticancer Research, 2007 - ar.iiarjournals.org
Background: Previous investigations showed antitumor properties of dirhenium carboxylate
introduced to tumor-bearing animals at high doses. The development of liposomal forms of …
introduced to tumor-bearing animals at high doses. The development of liposomal forms of …
Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin
AV Shtemenko, P Collery, NI Shtemenko… - Dalton …, 2009 - pubs.rsc.org
A new dirhenium(III) complex cis-[Re2(GABA)2Cl5(H2O)]Cl·2H2O with zwitterionic γ-aminobutyrate
ligands was prepared and characterized by spectral methods and crystallography. …
ligands was prepared and characterized by spectral methods and crystallography. …
The rhenium (I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers
P Collery, V Veena, A Harikrishnan… - Investigational new drugs, 2019 - Springer
The rhenium(I)-diselenoether complex (Re-diSe) is a rhenium tricarbonyl-based drug chelated
by a diselenoether ligand. In this work, we compared its inhibitory effects on the hormone-…
by a diselenoether ligand. In this work, we compared its inhibitory effects on the hormone-…
Synthesis, structural characterization and biological activity against several human tumor cell lines of four rhenium (I) diseleno-ethers complexes: Re (CO) 3Cl (PhSe …
…, J d'Angelo, A Tomas, P Roussel, G Bastian, P Collery… - Polyhedron, 2011 - Elsevier
Four novel rhenium(I) diseleno-ethers complexes, namely Re(CO) 3 Cl(PhSe(CH 2 ) 2 SePh)
(5), Re(CO) 3 Cl(PhSe(CH 2 ) 3 SePh) (6), Re(CO) 3 Cl(HO 2 C–CH 2 Se(CH 2 ) 2 SeCH 2 …
(5), Re(CO) 3 Cl(PhSe(CH 2 ) 3 SePh) (6), Re(CO) 3 Cl(HO 2 C–CH 2 Se(CH 2 ) 2 SeCH 2 …
Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin
F Kratz, U Beyer, P Collery, F LECHENAULT… - Biological and …, 1998 - jstage.jst.go.jp
One strategy for improving the antitumor selectivity and toxicity profile of antitumor agents is
to design drug carrier systems with suitable transport proteins. Thus, four maleimide …
to design drug carrier systems with suitable transport proteins. Thus, four maleimide …